Skip Navigation

Neuro-Oncology 1999 1(1):61-68; doi:10.1093/neuonc/1.1.61
© 1999 by Society
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Paleologos, N. A.
Right arrow Articles by Cairncross, J. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Paleologos, N. A.
Right arrow Articles by Cairncross, J. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1999 by the Society forNeuro-Oncology

Treatment of oligodendroglioma: An update

Nina A. Paleologos1 and J. Gregory Cairncross

Evanston Northwestern Healthcare, Evanston, IL 60201[N.A.P.]; London Regional Cancer Centre, London,Ontario, Canada N6A 4L6 [J.G.C.]

1 Address correspondence and reprint requests to Nina A. Paleologos, MD,Division of Neurology, Evanston Hosptial, 2650 Ridge Avenue, Evanston, IL60201.


  Abstract

Oligodendrogliomas are rare primary brain tumors. Significant attention hasrecently been focused on these interesting neoplasms because of their uniquechemosensitivity and the durability of some of these responses. Surgery andradiation continue to play important roles in the treatment ofoliogodendrogliomas. Molecular genetic analyses have given new insight intothe allelic deletions that distinguish these tumors and their progression fromindolent to more aggressive forms. In the future, molecular genetic analysismay guide therapeutic decisions concerning patients with oligodendroglioma andmay help us learn more about how to best treat other malignant brainneoplasms.

Received July 31, 1998; Accepted October 1, 1998


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Neuro OncologyHome page
M. S. Nielsen, H. C. Christensen, M. Kosteljanetz, and C. Johansen
Incidence of and survival from oligodendroglioma in Denmark, 1943-2002
Neuro Oncology, June 1, 2009; 11(3): 311 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Brada, L. Viviers, C. Abson, F. Hines, J. Britton, S. Ashley, S. Sardell, D. Traish, A. Gonsalves, P. Wilkins, et al.
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas
Ann. Onc., December 1, 2003; 14(12): 1715 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Hong, A. W. Bollen, and J. F. Costello
The Contribution of Genetic and Epigenetic Mechanisms to Gene Silencing in Oligodendrogliomas
Cancer Res., November 15, 2003; 63(22): 7600 - 7605.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.